|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Howard Hughes Medical Institute and the
Departments of Medicine, Biochemistry, and Molecular Biophysics,
Washington University School of Medicine, St Louis, MO; and the
Department of Hematology, Hemostasis and Thrombosis Research Center,
Leiden University Medical Center, The Netherlands.
Some families affected by von Willebrand disease type 1 show high
penetrance with exceptionally low von Willebrand factor (VWF) levels.
Previously, a mutation associated with this dominant phenotype,
Cys1149Arg, was found to decrease the secretion of coexpressed normal
VWF, and the mutation was proposed to cause intracellular retention of
pro-VWF heterodimers. To demonstrate heterodimer formation, a model was
developed in which subunits could be distinguished immunologically and
by size. Recombinant VWF lacking domain A1 (dA1), A3 (dA3), or both
(dA13) was secreted efficiently as a full range of multimers.
Cotransfection of Cys1149Arg and dA13 resulted in the secretion of
multimeric VWF containing about 250 kd (Cys1149Arg) and about 210 kd
(dA13). Cell lysates contained pro-VWF forms of Cys1149Arg and dA13.
Immunoprecipitation with an antidomain A1 antibody recovered both
subunits in heterodimers, and subunit ratios were consistent with
random dimerization. Similar results were obtained for cotransfection
of Cys1149Arg and dA1. Normal VWF has a Cys1149-Cys1169 intrachain
bond. When cotransfected with normal VWF, Cys1149Arg or the double
mutant Cys1149Arg+Cys1169Ser caused a similar decrease in VWF
secretion, suggesting that an unpaired Cys1169 does not explain the
intracellular retention of Cys1149Arg. VWF Cys1149Arg was not secreted
from BHK cells but was degraded intracellularly within about 4 hours,
and the proteasome inhibitor lactacystin delayed its clearance more
than 16 hours. Thus, dominant von Willebrand disease type 1 may be caused by heterodimerization of mutant and normal subunits in the
endoplasmic reticulum followed by proteasomal degradation in the
cytoplasm. A similar dominant negative mechanism could cause
quantitative deficiencies of other multisubunit proteins.
(Blood. 2001;98:2973-2979) von Willebrand disease (VWD) is a bleeding disorder
with an estimated prevalence of about 100 per million, similar to or
higher than that of hemophilia A.1 Most patients with VWD
have "type 1" disease,2 which is characterized by a
decreased level of structurally and functionally normal von Willebrand
factor (VWF) and usually exhibits autosomal dominant inheritance. Type
1 VWD can be divided into 2 subgroups. The more common form shows
variable penetrance and variable severity even within the same family, whereas a less common subset of patients has high penetrance with a
clearly dominant inheritance pattern and exceptionally low VWF levels.
The VWF levels in these families may be less than 15% of normal, which
is much lower than expected for heterozygous VWF deficiency and
suggests that their mutant VWF subunits inhibit the incorporation of
normal subunits into secreted multimers.
Heterozygous mutations frequently impair the function of oligomeric
proteins, and the complex biosynthesis of VWF offers several targets
for such an effect.2,3 In the endoplasmic reticulum (ER),
pro-VWF subunits form disulfide-linked dimers through C-terminal "cystine knot" motifs. The pro-VWF dimers are transported
to the Golgi apparatus, where the propeptides are removed and
additional disulfide bonds are formed between D3 domains near the
N-termini of the mature subunits. The product is a gigantic multimeric
protein, often containing more than 40 subunits and exceeding 10 000
kd in mass. Mutant subunits can impair the progress of normal VWF subunits through this pathway by interfering with any of several steps. For example, many mutations have been identified that interfere with multimer assembly or stability, causing the loss of large multimers that characterizes VWD type 2A.4,5
Despite the relatively high prevalence of type 1 VWD, the genetic cause
remains elusive in most families. The few mutations known to cause
dominant VWD type 1 are within the D3 domain, near the site of the
N-terminal intersubunit disulfide bonds. One family from the
Netherlands had 3 affected members with VWF levels of 10% to 15% of
normal, associated with the mutation Cys1149Arg (numbered from the
initiation codon, or Cys386Arg if numbered from the N-terminus of the
mature subunit).6 Two unrelated Italian patients with a
similar phenotype had the mutation Cys1130Phe,6 and
another patient from Hungary had a mutation at the same residue, Cys1130Tyr.7 Families from Italy, Germany,8
and Hungary7 have been identified with the mutation
Arg1205His as the cause of VWD "Vicenza."9 The
phenotype has been described as type 1 or type 2M because the
multimers are normal or supranormal in size but their function in vitro
is variably normal or decreased. The apparent clustering of these
mutations within the D3 domain suggests they may act through a shared mechanism.
We previously reported that the mutation-associated Cys1149Arg caused
the intracellular retention of pro-VWF subunits in the ER of
transfected cells and markedly reduced the secretion of mutant VWF.
Furthermore, when the Cys1149Arg subunit was coexpressed with
recombinant normal VWF, the level of normal VWF secretion was
decreased.6 Our working hypothesis was that the normal and
mutant subunits formed heterodimers that, like homodimers of
Cys1149Arg, were retained in the ER. Such a mechanism would explain the
dominant negative effect of the Cys1149Arg mutation on VWF secretion.
However, the single amino acid difference between the normal and mutant
subunits prevented the direct demonstration of heterodimer formation.
We therefore developed a model system in which Cys1149Arg subunits
could be distinguished from a variant of VWF that could act as a
surrogate for normal subunits. The deletion of domains A1 (dA1) and A3
(dA3) proved to be compatible with efficient synthesis and secretion of
highly multimerized VWF. The subunits bearing these deletions were
easily resolved from full-length subunits by gel electrophoresis and
were not recognized by monoclonal antibodies against the A1 domain. The
results obtained substantiate several features of the proposed model
for how dominant negative VWD mutations can cause a highly penetrant
and relatively severe form of VWD type 1.
Plasmid construction
The disulfide loop of the VWF A1 domain was deleted as follows. Plasmid
pGEM-4ZNK11 was used as the template for 2 PCR reactions. The first reaction employed primers T7 (TCT AAT ACG ACT CAG TAT AGG GAG AC) and C1353a (CTG AGG CGC
CGT AGA AAT CGT GCA ACG GCG GTT C; NarI site
underlined), and the product was digested with HindIII and
NarI. The second reaction employed primers C1458 (ATG CGG CGC CGA CCT TGC CCC TGA AGC CCC
TCC T; NarI site underlined) and 227a (CCG ATC CTT CCA GGA
CGA ACG CCA), and the product was digested with NarI and
NcoI. The purified fragments were ligated with the 2.7 kilobase (kb) HindIII-NcoI fragment of pGEM-4ZNK. In the product pGEM-4ZNKdA1, the hexanucleotide NarI site,
GGCGCC, replaced the 561 base pairs that encode Cys1353-Cys1458 of the mature VWF subunit. The NgoMI-KpnI fragment of
pSVHVWF1.1 was replaced with the mutant
NgoMI-KpnI fragment of pGEM-4ZNKdA1, yielding the
plasmid pSVHVWFdA1.
The disulfide loop of the VWF dA3 was deleted in a similar fashion. The
1924-base pair KpnI-SacI fragment of pSVHVWF1
was cloned into pGEM-4Z (Promega, Madison, WI) to yield plasmid
pGEM-4ZKS. Two PCR reactions were designed such that an
NgoMI site (GCCGGC) replaced the sequence encoding
Cys1686-Cys1872. The product fragment was cloned into pGEM-4ZKSG to
generate plasmid pGEM-4ZKSdA3. The mutated
KpnI-SacI fragment of pGEM-4ZKSdA3 was ligated
with the 7.9 kb EcoRV-KpnI fragment and the 1.6 kb SacI-EcoRV fragment of pSVHVWF1.1 to generate
plasmid pSVHVWFdA3.
Deletion of both disulfide loops of dA1 and dA3 was accomplished by a
3-fragment ligation of the KpnI-SacI fragment of
pGEM-4ZKSdA3, the 7.4 kb EcoRV-KpnI, and 1.6 kb
SacI-EcoRV fragments of pSVHVWFdA1 to generate
the plasmid pSVHVWFdA13.
Expression of recombinant VWF
Stable expression of recombinant normal VWF and Cys1149Arg was achieved by cotransfecting Fur4BHK cells (a BHK cell line expressing recombinant human furin) with pSV2neo and either pSVHVWF1 or pSVHCys1149Arg. Cells were cultured in Opti-MEM I containing geneticin (500 µg/mL), and clones expressing normal VWF or Cys1149Arg were selected. Protein gel electrophoresis and immunoassay Analysis of recombinant VWF multimers was performed by sodium dodecyl sulfate (SDS)-agarose gel electrophoresis and Western blotting as previously described.15 VWF multimers were visualized with rabbit polyclonal horseradish peroxidase-labeled antihuman VWF antibody P0226 (Dako, Denmark) and the ECL chemiluminescence system (Amersham Pharmacia Biotech).Gel electrophoresis of recombinant VWF was performed as described16,17 on SDS-5% polyacrylamide gels (Bio-Rad, Hercules, CA). Proteins were transferred by electroblotting onto a polyvinylidene difluoride membrane (Bio-Rad), and VWF was detected as described for VWF multimers. Recombinant VWF antigen concentrations were measured by an enzyme-linked immunosorbent assay (ELISA) method16 using rabbit polyclonal antihuman VWF antibody 082 and rabbit polyclonal horseradish peroxidase-labeled antihuman VWF antibody P226 (Dako). Immunoprecipitation and analysis of recombinant VWF 293T cells were cotransfected with Cys1149Arg and either dA1 or dA13 (dA1 and dA3) as above. Recombinant VWF was immunoprecipitated18 overnight at 4°C with 5.8 µg antibody 082 or 4 µg antibody B710 19 and 7.5 µL (packed volume) protein A-Sepharose or protein G-Sepharose in 1 mL of 10 mM Tris-HCl (pH 7.5), 1 mM ethylenediaminetetraacetic acid, 150 mM NaCl, 0.02% sodium azide, 1% Nonidet P-40, and 0.1% SDS. Immunoprecipitates were analyzed on SDS polyacrylamide gels as described above. The exposed films (Kodak XAR-5) were scanned, and bands were quantitated using NIH Image software version 1.61. Calculations were based on the following considerations, which use the example of cotransfection with Cys1149Arg and dA13.Transfected cells may express Cys1149Arg and dA13 at different levels. The fractions of total VWF subunits represented by Cys1149Arg and dA13 are a and b, respectively, and a + b = 1. Polyclonal antibody 082 immunoprecipitates all pro-VWF dimers. After gel electrophoresis under reducing conditions and quantitation of bands corresponding to Cys1149Arg and dA13 subunits, the ratio Cys1149Arg/dA13 082 is equal to a/b. If pro-VWF subunits dimerize randomly in the ER, the proportions of the possible dimers are given by (a + b)2 = a2 + 2ab + b2 where a2 is the fraction of Cys1149Arg homodimer, 2ab is the fraction of dA13-Cys1149Arg heterodimer, and b2 is the fraction of dA13 homodimer. Monoclonal antibody B710 is specific for dA119 and immunoprecipitates dimeric species that contain the Cys1149Arg subunit. The dimers recovered correspond to species a2 + 2ab (equation 1). Each a2 species contains 2 Cys1149Arg subunits, and each 2ab species contains 1 Cys1149Arg and 1 dA13 subunit. Therefore, the number of Cys1149Arg subunits recovered is proportional to 2a2 + 2ab, and the number of dA13 subunits recovered is proportional to 2ab. If dimerization is random, the expected ratio of Cys1149Arg/dA13 B710 is Cys1149Arg/dA13 B710 = (2a2 + 2ab)/2ab = a/b + 1. A tendency to avoid heterodimerization would increase the ratio Cys1149Arg/dA13B710, and a tendency to prefer heterodimerization would reduce the ratio Cys1149Arg/dA13B710 toward the limiting value of unity. Pulse-chase labeling Fur4BHK cell lines expressing recombinant normal VWF or Cys1149Arg were cultured to 70% to 90% confluence in 6-well plates, washed with phosphate-buffered saline, and incubated in cysteine-free and methionine-free medium for 1 hour. The medium then was supplemented with 100 µCi (3.7 × 106 becquerel) of 35S-labeled cysteine plus methionine (ICN Pharmaceuticals, Costa Mesa, CA) for 30 minutes, after which the cells were washed with phosphate-buffered saline and incubated in Opti-MEM I medium containing a 10-fold increased concentration of unlabeled cysteine and methionine. Conditioned media and cell lysates were prepared at the indicated times, and VWF was immunoprecipitated with antibody 082 as described18 except that a preclearing step without antibody was added. Samples were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) as described above. Gels were fixed, treated with Amplify (Amersham, Cleveland, OH), dried, and exposed to Kodak XAR-5 film at 80° C. If lactacystin (10 µM) was used, it was
present during the 1-hour preincubation with cysteine-free and
methionine-free medium as well as the pulse labeling and chase periods.
Deletion of the A1 or A3 domain does not interfere with VWF biosynthesis Mutations in one VWF allele can have a dominant effect and determine the properties of multimeric VWF provided that mutant subunits interact with normal subunits at the stage of dimer formation in the ER or at the stage of multimer assembly in the Golgi apparatus. Such a dominant negative mechanism has been proposed for certain missense mutations that cause a severe and highly penetrant form of VWD type 1.6 However, a physical interaction between such mutant and normal subunits has not been demonstrated directly.This limitation was addressed by constructing versions of VWF that can
be distinguished from full-length subunits based on their size and
immunologic properties (Figure 1). In
construct dA1, most of the VWF A1 domain was deleted by replacing amino acid residues Cys1353-Cys1458 with a Gly-Ala dipeptide. In construct dA3, most of the A3 domain was deleted by replacing Cys1686-Cys1872 with an Ala-Gly dipeptide. The 2 deletions were combined in construct dA13. When expressed by transient transfection of COS-7 cells, all 3 constructs allowed the assembly and secretion of VWF multimers (Figure
1A). These results are consistent with previous studies demonstrating
that other deletions affecting dA1 or dA3 were compatible with the
assembly and secretion of VWF multimers.20,21 The deleted
subunits were easily distinguished from normal VWF by gel
electrophoresis under reducing conditions (Figure 1B). As expected, dA1
or dA3 was about 22 kd and dA13 was about 45 kd smaller than
full-length VWF. The apparently normal biosynthetic processing of these
constructs suggests they should be useful to study their intracellular
association with other VWF subunits that bear distinct mutations.
Pro-VWF subunits form heterodimers To determine whether heterodimerization of pro-VWF can occur, 293T cells were cotransfected with plasmids encoding the deleted subunit dA13 and the mutant full-length subunit Cys1149Arg (Figure 2). Control experiments showed that dA13 was immunoprecipitated from cell lysates or conditioned medium using a polyclonal antibody to VWF. Also, monoclonal antibody B710, which recognizes an epitope within dA1, recognized construct Cys1149Arg but not construct dA13, as required. When both constructs were coexpressed in the same cells, immunoprecipitation of cell lysates with antibody B710 led to the recovery of both Cys1149Arg and dA13 pro-VWF subunits. Multimer gel electrophoresis under nonreducing conditions confirmed that cell lysates contained dimers and no multimers (data not shown). These results demonstrate the formation of heterodimers in the ER.
Although Cys1149Arg is secreted with low efficiency in transiently transfected 293T cells,6 immunoprecipitation of concentrated conditioned medium with B710 was able to recover some mature processed forms of both Cys1149Arg and dA13 (Figure 2, lane 8). The ratio of Cys1149Arg to dA13 is much more than 1:1 in this immunoprecipitate, which reflects the poor ability of Cys1149Arg subunits to form multimers.6 Because of this defect, most Cys1149Arg subunits would be found in homodimers and very small multimers, accompanied by relatively few dA13 subunits. Consequently, immunoprecipitation with B710 should recover mainly Cys1149Arg subunits from conditioned medium of cells transfected with both Cys1149Arg and dA13, as observed in this experiment. Dimerization of pro-VWF appears to be a random reaction The efficiency of heterodimerization was assessed by densitometric analysis of pro-VWF species recovered from cell lysates. Polyclonal antibody 082 immunoprecipitates all VWF species present in the cells (data not shown) and therefore permits the determination of the ratio of Cys1149Arg to dA1 (Figure 3A) or dA13 (Figure 3B), which may vary depending on the efficiency with which the subunits are expressed in a given experiment. Monoclonal antibody B710 recognizes only dimers containing the Cys1149Arg subunit, and immunoprecipitation with B710 excludes homodimers of dA1 or dA13. Immunoprecipitation with excess B710 recovers about 50% of the total Cys1149Arg subunits in lysates (data not shown). B710 is sensitive to conformation,19 and this result suggests that some A1 domains in the ER do not have a native structure.
A random dimerization mechanism predicts that the ratio Cys1149Arg/dA1 or Cys1149Arg/dA13 recovered with B710 will increase by 1.0 (equation 2) compared with the values obtained with antibody 082. The observed ratios are close to these expectations (Figure 3). This result eliminates limiting models of exclusive heterodimer formation and exclusive homodimer formation and is consistent with random dimerization of pro-VWF species in the ER. Some deviation from purely random dimerization cannot be ruled out because Cys1149Arg subunits were not quantitatively recovered in the B710 immunoprecipitates. Cys1169 is not required for intracellular retention of mutant Cys1149Arg In normal VWF, an intrasubunit disulfide bond22 connects Cys1149 to Cys1169, and the mutation Cys1149Arg leaves Cys1169 potentially unpaired, which could prevent exit from the ER.23,24 To determine whether the thiol group at Cys1169 contributes to the intracellular retention of Cys1149Arg subunits, constructs with the substitutions Cys1149Arg, Cys1169Ser, or both were prepared for cotransfection with normal VWF (Figure 4). As reported previously,6 coexpression of Cys1149Arg decreased the secretion and increased the intracellular concentration of VWF. The mutation Cys1169Ser and the double mutation Cys1149Arg+Cys1169Ser had a similar phenotype. Notably, adding the second mutation Cys1169Ser did not reduce the severity of the Cys1149Arg phenotype. Therefore, the thiol group of Cys1169, which may be unpaired when Cys1149 is mutated, does not appear to account for the intracellular retention of Cys1149Arg.
Pro-VWF Cys1149Arg is degraded by the proteasome Proteins that cannot escape the ER may be transported to the cytoplasm for proteolytic degradation by the proteasome.25 To investigate the fate of intracellular pro-VWF dimers, a pulse-chase experiment was performed in the presence and absence of lactacystin, a specific proteasome inhibitor26 (Figure 5). In Fur4BHK cells expressing normal VWF, secretion of VWF was detected by 4 hours of chase and was complete within 16 hours. Intracellular pro-VWF species disappeared from the cells over a similar time (Figure 5A). Lactacystin delayed the secretion of VWF and prolonged its clearance from the ER. In contrast to these results for normal VWF, cells expressing Cys1149Arg did not secrete detectable amounts of VWF, and the intracellular cohort of labeled molecules was degraded almost completely by 4 hours (Figure 5B). The complete failure of Cys1149Arg secretion seen in this pulse-chase experiment was confirmed by ELISA on conditioned medium (data not shown), indicating that stably transfected BHK cells retain these mutant VWF subunits even more efficiently than transiently transfected 293T cells (Figure 2). Lactacystin delayed the removal of mutant pro-VWF Cys1149Arg subunits to more than 16 hours, indicating that the destruction of intracellular Cys1149Arg involved retrograde transport into the cytoplasm and proteasomal degradation.
Although the molecular mechanism of type 1 VWD remains elusive in most families, there seems to be clear heterogeneity among type 1 VWD patients. Some families have low penetrance and a moderate decrease in VWF levels to 30 to 45 U/dL in affected members, whereas other families exhibit complete penetrance and a more severe decrease in VWF, often to 10 to 15 U/dL. The VWF mutation Cys1149Arg was identified in one family with highly penetrant VWD type 1, and this mutation was shown to dominantly suppress the secretion of normal VWF when coexpressed in 293T cells. To explain this phenotype, the mutant subunit was proposed to form heterodimers with normal VWF that were retained intracellularly and degraded. However, we could not determine whether a physical association of mutant and normal subunits occurred in the ER as well as in the Golgi apparatus, and heterodimer formation was not demonstrated directly.6 To study the mechanism responsible for dominant negative VWD type 1, we developed a model system in which 2 "alleles" could be distinguished. VWF biosynthesis is tolerant of certain large deletions, as shown by the efficient assembly and secretion of multimers composed of subunits lacking dA1 or dA3.20,21 The combined deletion of both dA1 and dA3 also was compatible with apparently normal multimer secretion (Figure 1A), and the larger deletion facilitates the differentiation of full-length and deleted subunits upon gel electrophoresis (Figure 1B). These properties enabled constructs lacking the A1 domain to serve as surrogates for a normal VWF "allele" that could be distinguished from full-size Cys1149Arg subunits by their smaller mass and lack of reactivity with anti-A1 domain antibodies. When both Cys1149Arg and dA13 subunits were expressed in 293T cells, immunoprecipitation of cell lysates with antibody B710 resulted in the recovery of both full-length Cys1149Arg and deleted dA13 pro-VWF subunits, proving that they form heterodimers within the ER (Figure 2). VWF subunits encoded by 2 alleles must be synthesized on different polyribosomes, and heterodimerization in the ER might be disfavored by the spatial separation of these translation events. However, densitometric analysis of subunit ratios indicates that pro-VWF dimerization is random (Figure 3). The site of interchain disulfide bond formation is within the extreme C-terminal 90 amino acid residues of the VWF subunit,27 and for this reason dimerization probably is not cotranslational but may occur instead after the release of polypeptide chains into the lumen of the ER. In addition, the intracellular retention and degradation of Cys1149Arg subunits presumably involves the persistent association of chaperones with misfolded segments near the N-terminus of the polypeptide, but this process does not impair the dimerization activity of the cystine knot domain at the C-terminus. Random dimerization of pro-VWF implies that one-half of all dimers will be heterodimers, and the retention of all mutant homodimers and heterodimers in the ER would reduce the secretion of VWF to 25% of the total synthesized. If the plasma concentration were proportional to synthesis, the corresponding mean plasma VWF level would average 25 U/dL. Patients with the heterozygous Cys1149Arg mutation have even lower VWF levels of 10 to 15 U/dL, and the cause of the more severe reduction is not known.6 The normal range of plasma VWF is broad and is influenced by several factors, such as ABO blood type and hormonal status. For example, the mean VWF levels in people of blood type O is 75 U/dL, with a range (± 2 SD) of 36 to 157 U/dL.28 Thus, combining the mutation Cys1149Arg and blood type O might lower the VWF level to the range observed for patients with the Cys1149Arg mutation. However, this explanation does not seem to apply, because unaffected family members had VWF levels of 83 to 86 U/dL and ABO blood type did not correlate with VWF level among the affected family members.6 An alternative mechanism to produce lower than predicted VWF levels could be proposed if a small fraction of dimers containing mutant subunits escaped from the ER and were incorporated into multimers in the Golgi apparatus. Escaped malfolded proteins apparently are retrieved from the distal secretory pathway,29,30 and the return of hetero-oligomers to the ER might remove additional normal subunits without substantially changing the size distribution of the final secreted multimers. This model predicts that when dimers escape from the ER, the subsequent biosynthetic steps should be normal, including multimerization in the Golgi, storage in Weibel-Palade bodies, secretion, and intravascular survival. In keeping with this model, the VWF multimer pattern of affected patients was normal and administration of DDAVP caused a marked elevation of plasma VWF concentration into the normal range (data not shown). Unpaired cysteines are known to prevent the intracellular transport of
many proteins and might contribute to the phenotype of VWF Cys1149Arg.
For example, treatment of cells with reducing agents causes the
reversible accumulation of several proteins within the ER, including
influenza virus hemagglutinin,31 albumin, and the
asialoglycoprotein receptor,32 but has no effect on The ER retention and degradation of pro-VWF heterodimers raises interesting questions about quality control mechanisms for protein synthesis. Newly translated proteins are recognized by resident ER chaperones and are retained until they fold properly.34 The signals for the detection of misfolding are not known, but at least some appear to be "local," and a large protein can have some misfolded domains that continue to bind certain chaperones and other folded domains that do not.35 Mutant VWF Cys1149Arg appears to fit this model because the mutation near its N-terminus causes ER retention without impairing the dimerization activity of the cystine knot domain at its C-terminus, more than 1500 amino acids and about 30 nm distant.36,37 Most retained cellular proteins are degraded by proteasomes in the cytoplasm, and the process probably involves the reduction of disulfide bonds, polypeptide unfolding, and retrotranslocation through a pore in the ER membrane.34 The stabilization of Cys1149Arg by the proteasome inhibitor lactacystin (Figure 5) is consistent with this mechanism, and the dominant phenotype of the heterozygous Cys1149Arg mutation suggests that a localized folding defect in the mutant subunit is sufficient to ensnare the disulfide-linked normal subunit as well. At some point in the retrotranslocation process, the subunits may be separated by the reduction of intersubunit disulfide bonds. If so, by then both subunits appear to be marked by an unknown mechanism for degradation. The dominant negative mechanism proposed for heterozygous VWF
Cys1149Arg may apply more generally to other multimeric proteins. If a
mutation causes the ER retention of a subunit without preventing its
assembly with normal subunits, the entire complex could be retained and
degraded. These conditions may be more likely to be fulfilled for
proteins with intersubunit disulfide bonds and several independently
folded domains, so that a structure remote from a site of covalent
oligomerization mediates ER retention. As a potential example among
hemostatic proteins, fibrinogen has the polypeptide composition
(
We thank Dr Dominique Meyer for providing monoclonal antibody B710.
Submitted June 30, 2000; accepted July 3, 2001.
Supported in part by grant DK50053 from the National Institutes of Health.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: J. Evan Sadler, Howard Hughes Medical Institute, Washington University School of Medicine, 660 South Euclid Ave, Box 8022, St Louis, MO 63110; e-mail: esadler{at}im.wustl.edu.
1. Holmberg L, Nilsson IM. von Willebrand's disease. Eur J Haematol. 1992;48:127-141[Medline] [Order article via Infotrieve]. 2. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395-424[CrossRef][Medline] [Order article via Infotrieve]. 3. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6:217-246[CrossRef].
4.
Lyons SE, Bruck ME, Bowie EJW, Ginsburg D.
Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations.
J Biol Chem.
1992;267:4424-4430 5. Ginsburg D, Sadler JE. von Willebrand disease: a database of point mutations, insertions, and deletions. Thromb Haemost. 1993;69:177-184[Medline] [Order article via Infotrieve].
6.
Eikenboom JCJ, Matsushita T, Reitsma PH, et al.
Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor.
Blood.
1996;88:2433-2441 7. Bodó I, Katsumi A, Tuley EA, et al. Mutations causing dominant type 1 von Willebrand disease with high penetrance. Blood. 1999;94(suppl 1):373a. 8. Schneppenheim R, Federici AB, Budde U, et al. Von Willebrand Disease type 2M "Vicenza" in Italian and German patients: identification of the first candidate mutation (G3864A; R1205H) in 8 families. Thromb Haemost. 2000;83:136-140[Medline] [Order article via Infotrieve].
9.
Mannucci PM, Lombardi R, Castaman G, et al.
von Willebrand disease "Vicenza" with larger-than-normal (supranormal) von Willebrand factor multimers.
Blood.
1988;71:65-70 10. Wagner DD, Saffaripour S, Bonfanti R, et al. Induction of specific storage organelles by von Willebrand factor propolypeptide. Cell. 1991;64:403-413[CrossRef][Medline] [Order article via Infotrieve].
11.
Dong Z, Thoma RS, Crimmins DL, et al.
Disulfide bonds required to assemble functional von Willebrand factor multimers.
J Biol Chem.
1994;269:6753-6758
12.
Dubridge RB, Tang P, Hsia HS, et al.
Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system.
Mol Cell Biol.
1987;7:379-387
13.
Chen C, Okayama H.
High-efficiency transformation of mammalian cells by plasmid DNA.
Mol Cell Biol.
1987;7:2745-2752
14.
Matsushita T, Sadler JE.
Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib: charged-to-alanine scanning mutagenesis of the A1 domain of human von Willebrand factor.
J Biol Chem.
1995;270:13406-13414 15. Raines G, Aumann H, Sykes S, Street A. Multimeric analysis of von Willebrand factor by molecular sieving electrophoresis in sodium dodecyl sulphate agarose gel. Thromb Res. 1990;60:201-212[CrossRef][Medline] [Order article via Infotrieve].
16.
Tuley EA, Gaucher C, Jorieux S, et al.
Expression of von Willebrand factor "Normandy": an autosomal mutation that mimics hemophilia A.
Proc Natl Acad Sci U S A.
1991;88:6377-6381 17. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685[CrossRef][Medline] [Order article via Infotrieve].
18.
Lyons SE, Cooney KA, Bockenstedt P, Ginsburg D.
Characterization of Leu777Pro and Ile865Thr type IIA von Willebrand disease mutations.
Blood.
1994;83:1551-1557 19. Pietu G, Ribba AS, Cherel G, et al. Epitope mapping of inhibitory monoclonal antibodies to human von Willebrand factor by using recombinant cDNA libraries. Thromb Haemost. 1994;71:788-792[Medline] [Order article via Infotrieve]. 20. Sixma JJ, Schiphorst ME, Verweij CL, Pannekoek H. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin. Eur J Biochem. 1991;196:369-375[Medline] [Order article via Infotrieve]. 21. Lankhof H, van Hoeij M, Schiphorst ME, et al. A3 domain is essential for interaction of von Willebrand factor with collagen type III. Thromb Haemost. 1996;75:950-958[Medline] [Order article via Infotrieve]. 22. Marti T, Rösselet SJ, Titani K, Walsh KA. Identification of disulfide-bridged substructures within human von Willebrand factor. Biochemistry. 1987;26:8099-8109[CrossRef][Medline] [Order article via Infotrieve].
23.
Kerem A, Kronman C, Bar-Nun S, Shafferman A, Velan B.
Interrelations between assembly and secretion of recombinant human acetylcholinesterase.
J Biol Chem.
1993;268:180-184 24. Fra AM, Fagioli C, Finazzi D, Sitia R, Alberini CM. Quality control of ER synthesized proteins: an exposed thiol group as a three-way switch mediating assembly, retention and degradation. EMBO J. 1993;12:4755-4761[Medline] [Order article via Infotrieve]. 25. Bonifacino JS, Weissman AM. Ubiquitin and the control of protein fate in the secretory and endocytic pathways. Annu Rev Cell Dev Biol. 1998;14:19-57[CrossRef][Medline] [Order article via Infotrieve].
26.
Fenteany G, Schreiber SL.
Lactacystin, proteasome function, and cell fate.
J Biol Chem.
1998;273:8545-8548
27.
Katsumi A, Tuley EA, Bodó I, Sadler JE.
Localization of disulfide bonds in the cystine knot domain of human von Willebrand factor.
J Biol Chem.
2000;275:25585-25594
28.
Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR.
The effect of ABO blood group on the diagnosis of von Willebrand disease.
Blood.
1987;69:1691-1695
29.
Hammond C, Helenius A.
Quality control in the secretory pathway: retention of a misfolded viral membrane glycoprotein involves cycling between the ER, intermediate compartment, and Golgi apparatus.
J Cell Biol.
1994;126:41-52
30.
Cole NB, Ellenberg J, Song J, DiEuliis D, Lippincott-Schwartz J.
Retrograde transport of Golgi-localized proteins to the ER.
J Cell Biol.
1998;140:1-15 31. Braakman I, Helenius J, Helenius A. Manipulating disulfide bond formation and protein folding in the endoplasmic reticulum. EMBO J. 1992;11:1717-1722[Medline] [Order article via Infotrieve].
32.
Lodish HF, Kong N.
The secretory pathway is normal in dithiothreitol-treated cells, but disulfide-bonded proteins are reduced and reversibly retained in the endoplasmic reticulum.
J Biol Chem.
1993;268:20598-20605
33.
Lentz SR, Sadler JE.
Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum.
Blood.
1993;81:683-689
34.
Ellgaard L, Molinari M, Helenius A.
Setting the standards: quality control in the secretory pathway.
Science.
1999;286:1882-1888 35. Ritter C, Helenius A. Recognition of local glycoprotein misfolding by the ER folding sensor UDP-glucose:glycoprotein glucosyltransferase. Nat Struct Biol. 2000;7:278-280[CrossRef][Medline] [Order article via Infotrieve]. 36. Fowler WE, Fretto LJ, Hamilton KK, Erickson HP, McKee PA. Substructure of human von Willebrand factor. J Clin Invest. 1985;76:1491-1500.
37.
Fretto LJ, Fowler WE, McCaslin DR, Erickson HP, McKee PA.
Substructure of human von Willebrand factor: proteolysis by V8 and characterization of two functional domains.
J Biol Chem.
1986;261:15679-15689
38.
Duga S, Asselta R, Santagostino E, et al.
Missense mutations in the human beta fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion.
Blood.
2000;95:1336-1341
39.
Brennan SO, Wyatt J, Medicina D, Callea F, George PM.
Fibrinogen brescia: hepatic endoplasmic reticulum storage and hypofibrinogenemia because of a 40. Wehinger H, Klinge O, Alexandrakis E, et al. Hereditary hypofibrinogenemia with fibrinogen storage in the liver. Eur J Pediatr. 1983;141:109-112[CrossRef][Medline] [Order article via Infotrieve].
41.
Lamande SR, Chessler SD, Golub SB, et al.
Endoplasmic reticulum-mediated quality control of type I collagen production by cells from osteogenesis imperfecta patients with mutations in the pro
42.
Bogaert R, Tiller GE, Weis MA, et al.
An amino acid substitution (Gly853
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  A. Perez-Rodriguez, A. Garcia-Rivero, E. Loures, M. F. Lopez-Fernandez, A. Rodriguez-Trillo, and J. Batlle Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications Haematologica, May 1, 2009; 94(5): 679 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Haberichter, G. Castaman, U. Budde, I. Peake, A. Goodeve, F. Rodeghiero, A. B. Federici, J. Batlle, D. Meyer, C. Mazurier, et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: Molecular and Clinical Markers for the Diagnosis and Management of Type 1 VWD (MCMDM-1VWD) Blood, May 15, 2008; 111(10): 4979 - 4985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.-H. Huang, Y. Wang, R. Roth, X. Yu, A. R. Purvis, J. E. Heuser, E. H. Egelman, and J. E. Sadler Assembly of Weibel Palade body-like tubules from N-terminal domains of von Willebrand factor PNAS, January 15, 2008; 105(2): 482 - 487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Purvis, J. Gross, L. T. Dang, R.-H. Huang, M. Kapadia, R. R. Townsend, and J. E. Sadler Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi PNAS, October 2, 2007; 104(40): 15647 - 15652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lorenz, B. Hewing, J. Hui, A. Zepp, G. Baumann, A. Bindereif, V. Stangl, and K. Stangl Alternative splicing in intron 13 of the human eNOS gene: a potential mechanism for regulating eNOS activity FASEB J, May 1, 2007; 21(7): 1556 - 1564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Michiels, H. H. D. M. van Vliet, Z. Berneman, A. Gadisseur, M. van der Planken, W. Schroyens, A. van der Velden, and U. Budde Intravenous DDAVP and Factor VIII-von Willebrand Factor Concentrate for the Treatment and Prophylaxis of Bleedings in Patients With von Willebrand Disease Type 1, 2 and 3 Clinical and Applied Thrombosis/Hemostasis, January 1, 2007; 13(1): 14 - 34. [Abstract] [PDF]
|
|
|
|
|
|
P. D. James, C. Notley, C. Hegadorn, J. Leggo, A. Tuttle, S. Tinlin, C. Brown, C. Andrews, A. Labelle, Y. Chirinian, et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study Blood, January 1, 2007; 109(1): 145 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Michiels, Z. Berneman, A. Gadisseur, M. van der Planken, W. Schroyens, A. van de Velde, and H. van Vliet Characterization of Recessive Severe Type 1 and 3 von Willebrand Disease (VWD), Asymptomatic Heterozygous Carriers Versus Bloodgroup O-Related von Willebrand Factor Deficiency, and Dominant Type 1 VWD Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 277 - 295. [Abstract] [PDF]
|
|
|
|
|
|
D. V. Kravtsov, P. E. Monahan, and D. Gailani A classification system for cross-reactive material-negative factor XI deficiency Blood, June 15, 2005; 105(12): 4671 - 4673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Purvis and J. E. Sadler A Covalent Oxidoreductase Intermediate in Propeptide-dependent von Willebrand Factor Multimerization J. Biol. Chem., November 26, 2004; 279(48): 49982 - 49988. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. V. Kravtsov, W. Wu, J. C. M. Meijers, M.-F. Sun, M. A. Blinder, T. P. Dang, H. Wang, and D. Gailani Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain Blood, July 1, 2004; 104(1): 128 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. O'Brien, P. D. James, M. Othman, E. Berber, C. Cameron, C. R. P. Notley, C. A. Hegadorn, J. J. Sutherland, C. Hough, G. E. Rivard, et al. Founder von Willebrand factor haplotype associated with type 1 von Willebrand disease Blood, July 15, 2003; 102(2): 549 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Wu, F. Wu, J. Pan, J. Morser, and Q. Wu Furin-mediated Processing of Pro-C-type Natriuretic Peptide J. Biol. Chem., July 3, 2003; 278(28): 25847 - 25852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Sadler Von Willebrand disease type 1: a diagnosis in search of a disease Blood, March 15, 2003; 101(6): 2089 - 2093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Rosenberg, S. L. Haberichter, M. A. Jozwiak, E. A. Vokac, P. A. Kroner, S. A. Fahs, Y. Kawai, and R. R. Montgomery The role of the D1 domain of the von Willebrand factor propeptide in multimerization of VWF Blood, August 13, 2002; 100(5): 1699 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Castaman, F. Rodeghiero, P. M. Mannucci, A. Casonato, E. Pontara, F. Sartorello, M. G. Cattini, and A. Girolami The elusive pathogenesis of von Willebrand disease Vicenza Blood, May 13, 2002; 99(11): 4243 - 4245. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
1-antitrypsin, which lacks disulfide
bonds.
)2, and autosomal dominant forms of
hypofibrinogenemia could include additional instances of this mechanism, particularly among patients with missense mutations that
impair subunit synthesis
Arg mutation.
Am J Pathol.
2000;157:189-196